Lazova R, Seeley EH, Keenan M, et al
Importantly, liver transcriptomic analysis demonstrated that semaglutide reduced the expression of genes involved in hepatic steatosis, inflammation, and fibrosis, which was confirmed histologically for steatosis and inflammation, but not for fibrosis [33]
We can see very clearly that this is specific to medications that are working through GLP-1 receptor pharmacology. In two other clinical trials, funded by pharmaceutical companies, which were not included in the meta-analysis due to methodological differences, the drug responses were similar between carriers and non-carriers
Of note, all the studies undertaken in the OCC included in this meta-analysis used 3 T MRS strength, whereas there was variation in MRS strength across the other brain regions (7 T was used for two MFC studies, with 3 T used for three MFC studies)
But going in with realistic expectations about side effects is important